Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191256 | 0.81 | ALDH1A1 (0.63) | ALDH1A1CHRNB2CHRNB4CHRNA4PHF8 | |
| SCHEMBL11696398 | 0.75 | TSHR (0.65) | ALDH1A1CHRNB2CHRNB4CHRNA4PHF8 | |
| SCHEMBL29588901 | 0.73 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL104328 | 0.72 | — | — | |
| SCHEMBL4019745 | 0.70 | PHF8 (0.39) | ALDH1A1PHF8KDM2AMEN1KMT2A | |
| SCHEMBL1071900 | 0.70 | ALDH1A1 (0.59) | ALDH1A1CHRNB2CHRNB4CHRNA4PHF8 | |
| SCHEMBL8645183 | 0.70 | — | — | |
| SCHEMBL322794 | 0.70 | PHF8 (0.64) | ALDH1A1CHRNB2CHRNB4CHRNA4PHF8 | |
| SCHEMBL10578272 | 0.70 | ALDH1A1 (0.52) | ALDH1A1CHRNB2CHRNB4CHRNA4PHF8 | |
| SCHEMBL16816192 | 0.70 | ALDH1A1 (0.52) | ALDH1A1CHRNB2CHRNB4CHRNA4PHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664011-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20080287489-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
| EP-1664011-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005020917-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287489-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNJ11 | ALDH1A1 899/4885CHRNB2 229/4885CHRNB4 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.